J&J and Merck Ebola vaccines produce lasting antibodies in children and adults
According to a study published in The New England Journal of Medicine, the Johnson & Johnson's and Merck's vaccines for Ebola created lasting antibodies.
Merck in talks to buy cancer biotech Seagen: report
Merck & Co is reportedly in talks to acquire biotech company Seagen Inc. in a nearly $40 billon deal that would add to the company's cancer drug portfolio.
Merck COVID-19 pill success slams Moderna shares, shakes up health care sector
Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.
Merck to request emergency approval for COVID-19 antiviral pill
Merck will request emergency approval for an experimental oral COVID-19 antiviral drug, molnupiravir, after a late-stage trial indicated an approximate 50% risk reduction for hospitalization or death among patients with mild to moderate COVID-19.
Merck says COVID-19 antiviral pill effective against variants
Molnupiravir, an experimental oral COVID-19 antiviral drug, could potentially be effective against all known variants of the coronavirus, according to its producer, a drug company called Merck.
Merck buying Acceleron Pharma in $11.5B deal
Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs heart.
Merck ends COVID-19 vaccine program, cites inferior immune responses
Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral expected by the end of March.
Strong sales of drugs, vaccines, propel Merck in third quarter
The Kenilworth, New Jersey, company on Tuesday reported a profit of $1.16 per share. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to $1.74 per share.
Merck Covid-19 vaccine begins human testing
The Wall Street Journal is reporting that Merck & Co. has begun testing one of its experimental Covid-19 vaccine candidates in healthy volunteers.
Merck to buy cancer drug developer ArQule for $2.7B in cash
The offer of $20 per share for ArQule is more than double its closing price on Friday.